Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03255070
Other study ID # ARX788-1711
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 20, 2018
Est. completion date October 18, 2023

Study information

Verified date January 2024
Source Ambrx, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.


Description:

Phase 1a will determine the recommended Phase 2 dose (RP2D) in subjects with advanced cancer whose HER2 test results are in situ hybridization (ISH) positive or immunohistochemistry (IHC) 3+, based on safety, tolerability, PK findings and antitumor activity. Phase 1b will assess the safety, tolerability, and PK and anticancer activity in five expansion cohorts, including breast cancer, gastric cancer / gastroesophageal adenocarcinoma, and other advanced HER2-positive solid tumors.


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date October 18, 2023
Est. primary completion date September 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >18 years - Life expectancy >3 months. - Female or male subjects whose advanced HER2 expressing cancer has failed standard of care treatments, or for whom such therapy is not acceptable to the subject. Subjects with advanced breast, gastric cancer, or other solid tumor who test positive for HER2 by ASCO/CAP criteria (either IHC or FISH) must have received prior treatment with a trastuzumab containing therapy. Subjects who have been previously treated with pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed therapies or investigational therapies are eligible. - Disease measurability: - Phase 1a: measurable or non-measurable disease per RECIST v 1.1. - Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b). - Histopathologic evidence of cancer based upon pathology report. - Tumor tissue local laboratory HER2 testing results, adequate tumor sample available for confirmation of HER2 status. Subjects with other types of cancer must have previously tested locally for HER2 status by HER2 IHC or ISH assay. - Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or gastric/esophageal or other solid tumors). - Phase 1b: Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH); Cohort 9 advanced breast cancer (IHC 2+ / ISH-); Cohort 10 advanced gastric cancer (IHC 3+ or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma; Cohort 11 other advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC 2+/IHS+); Cohort 12 advanced solid tumor cancers with HER2 activating mutation. - Eastern Cooperative Oncology Group Performance Status of 0 to 1. - Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b). - Adequate organ functions. - Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol. - Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or who commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment. - Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study. Exclusion Criteria: - History of allergic reactions to any component of ARX788. - History of ocular events, or any current ongoing active ocular infections. - History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment - Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0) - History of unstable central nervous system (CNS) metastases - Current severe, uncontrolled systemic disease (eg, clinical significant cardiovascular, pulmonary, or metabolic diseases) - Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments. - Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788. - Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788 - Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0. - Pregnancy or breast feeding. - Known active HCV, HBV, and/or HIV infection.

Study Design


Intervention

Drug:
ARX788
An antibody drug conjugate

Locations

Country Name City State
Australia Monash Health Clayton Victoria
Australia Research Site East Albury New South Wales
Australia Research Site Frankston Victoria
Australia Research Site Nedlands Western Australia
Australia Research Site North Sydney New South Wales
Australia Mater Misericordiae Limited South Brisbane Queensland
Australia Princess Alexandria Hospital Woolloongabba Queensland
United States Cleveland Clinic Cleveland Ohio
United States Baylor Sammons Cancer Center Dallas Texas
United States USC Norris Cancer Hospital Los Angeles California
United States Washington University School of Medicine Saint Louis Missouri
United States UCLA Hematology-Oncology Santa Monica California

Sponsors (1)

Lead Sponsor Collaborator
Ambrx, Inc.

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs) To assess the safety, tolerability, and immunogenicity profile Day 1 through 30 days after last dose
Primary Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1. Number of subjects with objective response is assessed every 6-8 weeks from Cycle 1 Day 1 through disease progression. 36 months
Secondary Number of subjects with tumor response per imaging assessment based on RECIST version 1.1. The objective response rate (ORR: CR+PR) based on RECIST v1.1 will be assessed as the primary endpoint to determine the anticancer activity of ARX788 as well as best overall response. 18 months
Secondary Area under the concentration-time curve (AUC) from first infusion to subject end of study. Pharmacokinetic (PK) characteristics: ARX788 (intact ADC), total mAb, and metabolites 36 months
Secondary Half-life of ARX788 from first infusion to end of study. Pharmacokinetic (PK) characteristics: ARX788 from first infusion to subject end of study 36 months
Secondary Immunogenicity profile of ARX788 Number of subjects who develop anti-ARX788 antibody 36 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Active, not recruiting NCT03664778 - Abbreviated Breast MRI After Cancer Treatment
Recruiting NCT03144622 - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed NCT05452499 - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae N/A
Active, not recruiting NCT04568902 - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Phase 1
Completed NCT02860585 - Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation N/A
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Completed NCT03698942 - Delphinus SoftVueâ„¢ ROC Reader Study
Completed NCT00092950 - Exercise in Women at Risk for Breast Cancer Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Not yet recruiting NCT02151071 - The Breast Surgery EnLight and LightPath Imaging System Study Phase 1/Phase 2
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Not yet recruiting NCT02876848 - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study) N/A
Completed NCT02931552 - Nuevo Amanecer II: Translating a Stress Management Program for Latinas N/A
Recruiting NCT02547545 - Breast Cancer Chemotherapy Risk Prediction Mathematical Model N/A
Completed NCT02303366 - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 Phase 1
Completed NCT02518477 - Preventive Intervention Against Lymphedema After Breast Cancer Surgery N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A